We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open Label, Study Of Efficacy and Safety Of AVR-RD-01 for Treatment-Naive Subjects With Classic Fabry Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03454893
Recruitment Status : Terminated (AVROBIO is deprioritizing its Fabry disease program)
First Posted : March 6, 2018
Last Update Posted : November 22, 2022
Sponsor:
Information provided by (Responsible Party):
AVROBIO

Brief Summary:
This is a multinational, open-label study to assess the efficacy and safety of AVR-RD-01 in approximately 8 to 12 male subjects 16 years of age or older and postpubertal with a confirmed diagnosis of classic Fabry disease based on deficient AGA enzyme activity who have not previously received treatment with enzyme replacement therapy (ERT) and/or chaperone therapy within 3 years of the time of Screening.

Condition or disease Intervention/treatment Phase
Fabry Disease Drug: AVR-RD-01 Phase 1 Phase 2

Detailed Description:

The duration of each subject's participation in this study will be approximately 64 weeks (or 1 year, 12 weeks), comprised of a five study periods (Screening, Baseline, Pre-transplant, Transplant, and Post-transplant Follow-up). During the Screening Period (approximately 8 weeks), written informed consent (and assent, if applicable) will be obtained and the subject will complete other Screening procedures to confirm study eligibility. Once study eligibility is confirmed, subjects will enter the Baseline Period (up to 3 days) during which time assessments will be performed to establish a pre-transplant baseline. Once baseline assessments are complete, the subject will enter the Pre-transplant Period (approximately 6 weeks) during which time mobilization, apheresis, AVR-RD-01 drug product preparation and testing for release, and conditioning regimen administration to achieve myeloablation will take place. Following completion of the Pre-transplant Period, the subject will enter the Transplant Period (1 day) during which time AVR-RD-01 infusion will take place. After AVR-RD-01 infusion, the subject will enter the Post-transplant Follow-up Period (approximately 48 weeks), during which time periodic safety and efficacy assessments will be performed to assess measures of engraftment, clinical response, and safety post-transplant.

After study completion, consenting subjects will continue periodic safety and efficacy assessments for approximately 14 years (for a total of 15 years post-transplant follow-up) in a long-term follow-up study to AVRO-RD-01-201.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multinational Study Of The Efficacy And Safety of Ex Vivo, Lentiviral Vector-Mediated Gene Therapy AVR-RD-01 For Treatment-Naive Subjects With Classic Fabry Disease
Actual Study Start Date : February 21, 2018
Actual Primary Completion Date : March 14, 2022
Actual Study Completion Date : March 14, 2022

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Single Assignment AVR-RD-01
AVR-RD-01 Drug Product (autologous CD34+ cell-enriched fraction that contains cells transduced with Lentiviral Vector/alpha-galactosidase A (AGA) encoding for the human AGA complementary deoxyribonucleic acid (cDNA) sequence
Drug: AVR-RD-01
The subject will receive a one-time IV infusion of AVR-RD-01.




Primary Outcome Measures :
  1. Incidence of and severity of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: Baseline to Week 48 post gene therapy ]
  2. Number of participants with clinically relevant abnormalities, as assessed by clinical laboratory tests [ Time Frame: Baseline to Week 48 post gene therapy ]
  3. Number of participants with clinically relevant abnormalities, as assessed by vital signs [ Time Frame: Baseline to Week 48 post gene therapy ]
  4. Number of participants with clinically relevant abnormalities as assessed by electrocardiograms (ECGs) [ Time Frame: Baseline to Week 48 post gene therapy ]
  5. Evaluation of immunogenicity of AVR-RD-01 [ Time Frame: Baseline to Week 48 post gene therapy ]
    Presence of anti-AGA antibodies

  6. Presence of replication competent lentivirus (RCL) [ Time Frame: Baseline to Week 48 post gene therapy ]
    Presence of RCL

  7. Evaluate for the presence of aberrant clonal expansion as assessed by integration site analysis (ISA) [ Time Frame: Baseline to Week 48 post gene therapy ]
  8. Evaluate the effect of AVR-RD-01 on substrate (ie, globotriaosylceramide [Gb3]) in kidney biopsies [ Time Frame: Baseline to Week 48 post gene therapy ]
    Change in the average number of Gb3 inclusions (ie, myelinosomes) per kidney peritubular capillary (PTC) per subject


Secondary Outcome Measures :
  1. Change from baseline in AGA enzyme activity level in plasma and peripheral blood leukocytes (PBLs) [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  2. Change from baseline in Globotriaosylceramide (Gb3) biomarkers for Fabry disease in plasma and urine [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  3. Change from baseline in substrate (i.e. Gb3) in skin biopsy [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  4. Change from baseline in renal function as assessed by measured glomerular filtration rate (mGFR) [ Time Frame: Baseline to Week 48 post gene therapy ]
  5. Change from baseline in renal function as assessed by estimated glomerular filtration rate (eGFR) [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  6. Change from baseline in renal function as assessed by urine total protein levels [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  7. Change from baseline in renal function as assessed by urine albumin levels [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  8. Change from baseline in left ventricular mass index (LVMI) as assessed by cardiac magnetic resonance imaging (MRI) [ Time Frame: Baseline to Week 48 post gene therapy ]
  9. Change from baseline in abdominal pain and stool consistency as assessed by the Diary for Irritable Bowel Syndrome Symptoms-Diarrhea (DIBSS-D) [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  10. Change from baseline in Brief Pain Inventory-Short Form (BPI-SF) questionnaire scores [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  11. Change from baseline in physical and mental functioning as assessed by the Short Form 36 (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) scores [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  12. Average Vector Copy Number (VCN) in peripheral blood leukocytes as assessed by quantitative polymerase chain reaction (qPCR) and/or droplet digital polymerase chain reaction (ddPCR) [ Time Frame: Baseline to Week 24 and Week 48 post gene therapy ]
  13. Average Vector Copy Number (VCN) in bone marrow / progenitor cells as assessed by quantitative polymerase chain reaction (qPCR) and/or droplet digital polymerase chain reaction (ddPCR) [ Time Frame: Baseline to Week 48 post gene therapy ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   16 Years to 50 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is male, 16 years of age or older (18 years of age or older in the US), and postpubertal,(minimum age by region)
  2. Subject has a confirmed diagnosis of classic Fabry disease based on deficient AGA enzyme activity (defined as < 1% of normal).

Exclusion Criteria:

  1. Subject has a GLA gene mutation associated with late-onset cardiac variant Fabry disease.
  2. Subject has previously received ERT and/or chaperone therapy within 3 years for treatment of Fabry disease.
  3. Subject has tested positive for anti-AGA antibodies at the time of screening.
  4. Subject has eGFR < 60 mL/min/1.73 m² (ie, chronic kidney disease [CKD] stage ≥ 3) at Screening.
  5. Subject has a prior history of myocardial infarction (MI).
  6. Subject has a history of coronary artery disease (CAD) with angina requiring percutaneous transluminal coronary angioplasty (with or without stent placement) and/or coronary artery bypass graft (CABG).
  7. Subject has a history of moderate to severe valvular heart disease requiring valve replacement.
  8. Subject has a history of heart failure, moderate to severe diastolic dysfunction, and/or left ventricular ejection fraction (LVEF) ≤ 45% on echocardiogram (ECHO) performed at rest at Screening.
  9. Subject has a history of clinically significant cardiac arrhythmia (eg, heart block [second or third degree], atrial fibrillation requiring therapy, ventricular fibrillation, ventricular tachycardia, supraventricular tachycardia, or cardiac arrest).

    Note [history of intermittent atrial fibrillation not requiring treatment is allowed].

  10. Subject has a prior history of stroke and/or transient ischemic attack (TIA).
  11. Subject has aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ≥ 3 times the upper limit of normal (ULN) at Screening.
  12. Subject has a prior history of (or current) malignancy; the one exception is a prior history of resected basal cell carcinoma.
  13. Subject has previously received treatment with AVR-RD-01 or any other gene therapy.

Other inclusion/exclusion criteria apply.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03454893


Locations
Layout table for location information
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, Pennsylvania
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States, 15213
Australia, Parkville VIC
Royal Melbourne Hospital
Melbourne, Parkville VIC, Australia
Australia
Royal Perth Hospital
Perth, Australia
Brazil
Hospital de Clinicas de Porto Alegre
Porto Alegre, Rio Grande Do Sul, Brazil
Sponsors and Collaborators
AVROBIO
Investigators
Layout table for investigator information
Study Director: Medical Director, MD AVROBIO, Inc
Layout table for additonal information
Responsible Party: AVROBIO
ClinicalTrials.gov Identifier: NCT03454893    
Other Study ID Numbers: AVRO-RD-01-201
First Posted: March 6, 2018    Key Record Dates
Last Update Posted: November 22, 2022
Last Verified: April 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AVROBIO:
Fabry disease
Cell therapy
Gene therapy
Lysosomal storage disorder
Lenti-viral
Additional relevant MeSH terms:
Layout table for MeSH terms
Fabry Disease
Sphingolipidoses
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Cerebral Small Vessel Diseases
Cerebrovascular Disorders
Vascular Diseases
Cardiovascular Diseases
Genetic Diseases, X-Linked
Genetic Diseases, Inborn
Metabolism, Inborn Errors
Lipidoses
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Lipid Metabolism Disorders